得力生和IL-2联合顺铂治疗恶性胸腔积液的疗效

Effect of Delisheng,interleukin-2 and PDD in treatment of malignant pleural effusion

目的:观察得力生和白细胞介素Ⅱ(IL-2)联合顺铂(PDD)治疗恶性胸腔积液的近期疗效和毒副反应。方法:58例恶性胸腔积液患者,先采用一次性单腔中心静脉导管,进行胸腔穿刺置管闭式引流胸水,再给予胸腔内注药,其中A组(n=32)白细胞介素Ⅱ加顺铂,B组(n=26)得力生加顺铂。白细胞介素Ⅱ每次注入200万U～300万U,得力生每次注入30ml～50ml,顺铂每次注入60mg～100mg,每周注射1次,连续注射3周,1个月观察两组的疗效及不良反应。结果:A组有效率81.3%(26/32),B组有效率76.9%(20/26),无显著性统计学差异(P>0.05)。结论:胸腔闭式引流后注入白细胞介素Ⅱ或得力生加顺铂,治疗恶性胸腔积液,疗效肯定,是控制恶性胸腔积液的有效方法。

To evaluate the response and adverse reaction of Delisheng, IL -2 and PDD in the treatment of malignant pleura1 effusion. Methods： Fifty night patients with malignant pleura1 effusion were treated with single lumen central venous catheters . All patients were received the closed thoracic drainage and divided into two groups . The patients in group A （ n = 32） were treated by intracavity injection of IL - 2 and PDD , the patients in group B （n = 26） were treated by intracavity injection of Delisheag and PDD, IL -2 at a dose of 2 ～ 3 ×106 u every time was injected intrapleurally. Delisheag was 30ml ~ 5Oral every time and PDD 80mg～ 100mg every time. The above therapy was given one time/week for 3 weeks. The therapeutic effect and adverse reactions were observed after one month. Results： Overall objective response rate （ CR ＋ PR） was 81.3% in the group A higher than that of 76.9% in the group B , but there was no significant difference （ P 〉 0. 05 ） . Conclusion： After draining completely the pleural fluid , the intracavity injection of IL - 2 or delisheng and PDD were effective for malignant pleura1 effusion .